EXTON, Pa.--(BUSINESS WIRE)--June 29, 2006--Rheologics Inc., a subsidiary of Rheologics Technologies, Inc. (OTC:RTGI; “Rheologics”, “the Company”), is pleased to announce that its signature product, the Rheolog(TM) was the primary device utilized in a prominent sickle cell disease (SCD) study published in this month’s edition of the American Association of Blood Banks’ scientific journal Transfusion. The research focused on the importance of whole blood viscosity measured across a wide range of shear rates in determining the optimum level of transfusion for sickle cell disease patients. With further clinical research, the findings may lead to improved sickle cell transfusion standards, including optimum hematocrit levels for transfusion, and hence to improved quality of care for patients with sickle cell disease.
